Related Experiment Video

Updated: Apr 11, 2026

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.1K

Transcriptome-wide Mendelian randomization during CD4+ T cell activation reveals immune-related drug targets for

Xueyan Wu1,2, Hui Ying1,2, Qianqian Yang1,2

  • 1Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.

Nature Communications
|October 29, 2024
PubMed

Insights

This study reveals immune system links to cardiometabolic diseases like type 2 diabetes and coronary artery disease. It identifies specific genes and potential drug targets within immune cells for future treatments.

Area of Science:

  • Immunology
  • Genetics
  • Cardiovascular Medicine
  • Metabolic Disease Research

Background:

  • Immunity plays a role in cardiometabolic diseases, including type 2 diabetes (T2D) and coronary artery disease (CAD).
  • Understanding immune system involvement can inform drug development for these conditions.

Purpose of the Study:

  • To investigate the causal relationship between gene expression in activated CD4+ T cells and the risk of T2D and CAD.
  • To identify specific immune-related genes and potential therapeutic targets for cardiometabolic diseases.

Main Methods:

  • A transcriptome-wide Mendelian randomization (MR) study was conducted.
  • Analyzed 11,021 gene expression profiles during CD4+ T cell activation.
  • Utilized robust MR and colocalization analyses to assess causality.

Main Results:

  • Identified 162 genes associated with T2D risk and 80 genes with CAD risk.
  • Found that 12% of T2D-associated genes and 16% of CAD-associated genes were specific to CD4+ T cells.
  • Observed temporal causal patterns for 69 gene-T2D and 34 gene-CAD pairs during T cell activation.
  • Discovered 25 genes, including LIPA and GCK, that are targets for drugs in clinical investigation.

Conclusions:

  • Established immune-to-metabolic disease connections, particularly for T2D and CAD.
  • Prioritized immune-mediated genes as potential drug targets for cardiometabolic diseases.
  • Highlighted the significance of CD4+ T cell gene expression in cardiometabolic disease etiology.

More Related Videos

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.8K
Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

1.2K

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
125
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
91